Blas K - Search Results

1

Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.

Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA. Stenmark MH, et al. Among authors: blas k. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e335-44. doi: 10.1016/j.ijrobp.2011.04.037. Epub 2011 Jun 7. Int J Radiat Oncol Biol Phys. 2011. PMID: 21645976

2

The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.

Qian Y, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra DA. Qian Y, et al. Among authors: blas k. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e135-42. doi: 10.1016/j.ijrobp.2011.01.007. Epub 2011 Feb 23. Int J Radiat Oncol Biol Phys. 2011. PMID: 21345617

3

Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation.

Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra DA. Sabolch A, et al. Among authors: blas k. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e351-60. doi: 10.1016/j.ijrobp.2011.01.063. Epub 2011 Apr 13. Int J Radiat Oncol Biol Phys. 2011. PMID: 21493015

4

The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse.

Halverson S, Schipper M, Blas K, Lee V, Sabolch A, Olson K, Sandler HM, Feng FY, Hamstra DA. Halverson S, et al. Among authors: blas k. Radiother Oncol. 2011 Dec;101(3):513-20. doi: 10.1016/j.radonc.2011.05.080. Epub 2011 Jun 22. Radiother Oncol. 2011. PMID: 21703711

5

Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy.

Feng FY, Qian Y, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA. Feng FY, et al. Among authors: blas k. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e361-7. doi: 10.1016/j.ijrobp.2011.04.048. Epub 2011 Aug 4. Int J Radiat Oncol Biol Phys. 2011. PMID: 21820250

6

Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.

Vance SM, Stenmark MH, Blas K, Halverson S, Hamstra DA, Feng FY. Vance SM, et al. Among authors: blas k. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):940-6. doi: 10.1016/j.ijrobp.2011.09.005. Epub 2011 Nov 4. Int J Radiat Oncol Biol Phys. 2012. PMID: 22056069

7

The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer.

Murgic J, Stenmark MH, Halverson S, Blas K, Feng FY, Hamstra DA. Murgic J, et al. Among authors: blas k. Radiat Oncol. 2012 Aug 1;7:127. doi: 10.1186/1748-717X-7-127. Radiat Oncol. 2012. PMID: 22852797 Free PMC article.

8

Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer.

Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, Albrecht-Unger L, Donaghy A, Phelps L, Blas K, Halverson S, Marsh R, Olson K, Feng FY. Hamstra DA, et al. Among authors: blas k. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1246-53. doi: 10.1016/j.ijrobp.2012.10.042. Epub 2012 Dec 19. Int J Radiat Oncol Biol Phys. 2013. PMID: 23265567

9

Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.

Feng FY, Blas K, Olson K, Stenmark M, Sandler H, Hamstra DA. Feng FY, et al. Among authors: blas k. Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):64-71. doi: 10.1016/j.ijrobp.2012.11.024. Epub 2013 Feb 22. Int J Radiat Oncol Biol Phys. 2013. PMID: 23462420

10

Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer.

Vu CC, Blas KG, Lanni TB, Gustafson GS, Krauss DJ. Vu CC, et al. Among authors: blas kg. Brachytherapy. 2018 Nov-Dec;17(6):852-857. doi: 10.1016/j.brachy.2018.07.009. Epub 2018 Jul 31. Brachytherapy. 2018. PMID: 30076108 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters